Publication & Citation Trends
Publications
30 total
Abstract 410: Characterization of CGT1263, a KRAS (ON/OFF) inhibitor clinical candidate with selectivity for mutant KRAS over HRAS and NRAS.
Cited by 0
Semantic Scholar
Abstract 5869: Preclinical characterization of CGT4255, an EGFR sparing, pan-mutant HER2 clinical development candidate with potential best-in-class brain penetration
Cited by 0
Semantic Scholar
Abstract P4-12-19: Preclinical Characterization of a Novel PI3Kα H1047R Mutant-Selective Inhibitor
Cited by 0
OpenAlex
Abstract 5623: Identification of CGT4255 an EGFR sparing, pan-mutant HER2 clinical development candidate with potential best-in-class brain penetration
Cited by 0
OpenAlex
Abstract B024: Identification of a potent KRAS (ON) inhibitor clinical candidate series with selectivity for mutant KRAS over HRAS and NRAS
Cited by 0
OpenAlex
Preclinical characterization of a novel, wild-type-sparing, JAK2 V617F mutant-selective inhibitor
Cited by 0
Semantic Scholar
Abstract 4729: The reversible and selective FGFR2/3 inhibitor CGT4859 has superior target coverage of resistance mutations missed by leading FGFR inhibitors
Cited by 1
Semantic Scholar
Abstract 3004: Preclinical characterization of CGT6297, a novel PI3Kα H1047R mutant-selective inhibitor
Cited by 0
Semantic Scholar
Research Topics
Cancer, Hypoxia, and Metabolism
(8)
Fibroblast Growth Factor Research
(4)
Lung Cancer Treatments and Mutations
(3)
HER2/EGFR in Cancer Research
(3)
Sirtuins and Resveratrol in Medicine
(3)
Affiliations
University of Science and Technology of China
University of Alberta
Pfizer (United States)
Cornell University
Hefei National Center for Physical Sciences at Nanoscale